Protease recognition enzymes, lentiviral recombinant vectors, cell lines and uses thereof

CN117417907BActive Publication Date: 2026-11-10THE FIRST AFFILIATED HOSPITAL OF SOOCHOW UNIV
View PDF 2 Cites 0 Cited by

Patent Information

Application Number
CN202311364108.4
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2023-10-20
Publication Date
2026-11-10
Estimated Expiration
2043-10-20

Smart Images

  • Figure SMS_1
    Figure SMS_1
  • Figure SMS_2
    Figure SMS_2
  • Figure SMS_3
    Figure SMS_3
Patent Text Reader

Abstract

The present application relates to the field of biotechnology, and particularly relates to protease recognition enzyme, lentivirus recombinant vector, cell line and application thereof. The present application provides a protease recognition enzyme, which has an amino acid sequence as shown in SEQ ID NO:1. The present application constructs A549-EGFPc and Hela-EGFPc cell lines for detecting proteasome activity in cells. Compared with the prior art protease recognition enzyme, the present application has a detection sensitivity improved by 30-40%, and the damage degree of proteasome can be quantitatively judged by the green fluorescence accumulation in the cell line; the present application also has a significant quantitative detection efficiency for the proteasome damage caused by virus infection, which makes up for the deficiency that the proteasome damage caused by virus infection cannot be quantitatively detected; the cell line constructed by the present application still has stability after 50 generations. Therefore, the present application is significantly improved in detection sensitivity, stability and application range, and has a wide application prospect and industrial use value.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] This invention relates to the field of biotechnology, and in particular to protease recognition enzymes, lentiviral recombinant vectors, cell lines, and their applications. Background Technology

[0002] The proteasome is a non-lysosomal protein degradation system in cells that relies on ATP activity. This system can efficiently and selectively degrade proteins through various mechanisms such as ubiquitination and phosphorylation. Most proteins in vivo are degraded via the proteasome system, and the level of proteasome activity directly determines the rate of protein degradation within cells. Proteasome activity plays a crucial role in regulating the cell cycle, cell death, and cellular stress responses. Current research has also found that decreased proteasome activity can lead to cardiovascular diseases such as congestive heart failure, making it a promising area for application in cardiovascular disease research.

[0003] Proteasome activity directly determines the rate at which host cells break down proteins, playing a crucial role in normal cellular metabolism. Viral infections, especially influenza, can impair proteasome activity and damage host cells. However, currently, there is a lack of indicators and systems for directly quantifying proteasome activity. Existing ubiquitination detection systems have limitations; they cannot directly detect the damage to proteasome activity caused by viral infections, nor can they detect the damage to the proteasome system caused by viral infections. Therefore, there is an urgent need for systems and cell lines that can directly quantify proteasome activity in cells, and the detection systems themselves urgently need improvement in terms of sensitivity, stability, and range. Summary of the Invention

[0004] In view of this, the present invention provides a protease recognition enzyme, a lentiviral recombinant vector, a cell line, and their applications. The present invention constructs an A549-EGFPc and HeLa-EGFPc cell line capable of quantitatively detecting intracellular proteasome activity. Compared to existing protease recognition enzymes, the present invention significantly improves the detection efficiency of proteasome activity, increasing detection sensitivity by 30-40%. The degree of proteasome damage can be quantitatively determined by the accumulation of green fluorescence in the A549-EGFPc and HeLa-EGFPc cell lines. This system also shows significant detection efficiency for proteasome damage directly caused by viral infections, compensating for the inability to quantitatively detect proteasome damage caused by viral infections. Furthermore, the cell line constructed by the present invention remains stable after 50 passages. Therefore, compared to existing systems, the present invention significantly improves detection sensitivity, detection stability, and detection range, possessing broad application prospects and industrial value.

[0005] To achieve the above-mentioned objectives, the present invention provides the following technical solution:

[0006] This invention provides a protease recognition enzyme having:

[0007] (1) An amino acid sequence as shown in SEQ ID NO:1; or

[0008] (2) An amino acid sequence obtained by substituting, deleting, or adding one or more amino groups to the amino acid sequence shown in (1), and which has the same or similar function as the amino acid sequence shown in (1); or

[0009] (3) An amino acid sequence that is at least 80% identical to the amino acid sequence shown in (1) or (2).

[0010] In some embodiments of the present invention, the sequence of the protease recognition enzyme is: SGLRSRAQASNSAVDGTACENWFSSLSHFVIHL (as shown in SEQ ID NO:1).

[0011] In some embodiments of the present invention, the name of the protease recognition enzyme is: CL-1.

[0012] The present invention also provides a nucleic acid molecule encoding the above-mentioned protease recognition enzyme, which has the following characteristics:

[0013] (4) A nucleotide sequence as shown in SEQ ID NO:2; or

[0014] (5) A nucleotide sequence obtained by substituting, deleting, or adding one or more bases to the nucleotide sequence shown in (4), and which has the same or similar function as the nucleotide sequence shown in (4); or

[0015] (6) A nucleotide sequence that is at least 80% identical to the nucleotide sequence shown in (4) or (5).

[0016] In some embodiments of the present invention, the sequence of the above nucleic acid molecule is: TCCGGACTCAG ATCTCGAGCTCAAGCTTCGAATTCTGCAGTCGACGGTACCGCCTGCGAG AACTGGTTTAGCAGCCTCTCTCACTTTGTGATCCACCTC (as shown in SEQ ID NO:2).

[0017] The present invention also provides a lentiviral recombinant vector, comprising the above-mentioned nucleic acid molecule, fluorescent protein gene and lentiviral vector.

[0018] In some embodiments of the present invention, the fluorescent protein gene in the lentiviral recombinant vector described above includes the EGFPc gene.

[0019] In some embodiments of the present invention, the sequence of the EGFPc gene in the above-mentioned lentiviral recombinant vector is as shown in SEQ ID NO:6: ATGGTGAGCAAGGGCGAGGAGCTGTTCA.

[0020] In some embodiments of the present invention, the fluorescent protein gene in the lentiviral recombinant vector described above includes the EGFPc gene.

[0021] In some embodiments of the present invention, the lentivirus recombinant vector described above includes pTrip-BSD.

[0022] In some embodiments of the present invention, the original lentivirus vector of the pTrip-BSD in the above-mentioned lentivirus recombinant vector is derived from: GenBank: OM859278.1, and the reference is: Sadic M, Schneider WM, Katsara O, et al. DDX60 selectively reduces translation off viral type II internal ribosome entry sites. EMBO Rep. 2022; 23(12):e55218. doi:10.15252 / embr.202255218.

[0023] In some embodiments of the present invention, the lentivirus recombinant vector described above is an optimized version of the original lentivirus vector.

[0024] In some embodiments of the present invention, the above-mentioned pTrip-BSD sequence is: TGGAAGGGC TAATTCACTCCCAAAGAAGACAAGATATCCTTGATCTGTGGATCTACCA

[0025] CACACAAGGCTACTTCCCTGATTAGCAGAACTACACACCAGGGCCAGG

[0026] GGTCAGATATCCACTGACCTTTGGATGGTGCTACAAGCTAGTACCAGTT

[0027] GAGCCAGATAAGGTAGAAGAGGCCAATAAAGGAGAGAACACCAGCTT

[0028] GTTACACCCTGTGAGCCTGCATGGGATGGATGACCCGGAGAGAGAAGT

[0029] GTTAGAGTGGAGGTTTGACAGCCGCCTAGCATTTCATCACGTGGCCCGA

[0030] GAGCTGCATCCGGAGTACTTCAAGAACTGCTGATATCGAGCTTGCTACA

[0031] AGGGACTTTCCGCTGGGGACTTTCCAGGGAGGCGTGGCCTGGGCGGGA

[0032] CTGGGGAGTGGCGAGCCCTCAGATCCTGCATATAAGCAGCTGCTTTTTG

[0033] CCTGTACTGGGTCTCTCTGGTTAGACCAGATCTGAGCCTGGGAGCTCTC

[0034] TGGCTAACTAGGGAACCCACTGCTTAAGCCTCAATAAAGCTTGCCTTGA

[0035] GTGCTTCAAGTAGTGTGTGCCCGTCTGTTGTGTGACTCTGGTAACTAGA

[0036] GATCCCTCAGACCCTTTTAGTCAGTGTGGAAAATCTCTAGCAGTGGCGC

[0037] CCGAACAGGGACTTGAAAGCGAAAGGGAAACCAGAGGAGCTCTCTCG

[0038] ACGCAGGACTCGGCTTGCTGAAGCGCGCACGGCAAGAGGCGAGGGGC

[0039] GGCGACTGGTGAGTACGCCAAAAATTTTGACTAGCGGAGGCTAGAAGG

[0040] AGAGAGATGGGTGCGAGAGCGTCAGTATTAAGCGGGGGAGAATTAGA

[0041] TCGCGATGGGAAAAAATTCGGTTAAGGCCAGGGGGAAAGAAAAAATA

[0042] TAAATTAAAACATATAGTATGGGCAAGCAGGGAGCTAGAACGATTCGC

[0043] AGTTAATCCTGGCCTGTTAGAAACATCAGAAGGCTGTAGACAAATACT

[0044] GGGACAGCTACAACCATCCCTTCAGACAGGATCAGAAGAACTTAGATC

[0045] ATTATATAATACAGTAGCAACCCTCTATTGTGTGCATCAAAGGATAGAG

[0046] ATAAAAGACACCAAGGAAGCTTTAGACAAGATAGAGGAAGAGCAAAA

[0047] CAAAAGTAAGACCACCGCACAGCAAGCGGCCGCTGATCTTCAGACCTG

[0048] GAGGAGGAGATATGAGGGACAATTGGAGAAGTGAATTATATAAATATA

[0049] AAGTAGTAAAAATTGAACCATTAGGAGTAGCACCCACCAAGGCAAAGA

[0050] GAAGAGTGGTGCAGAGAGAAAAAAGAGCAGTGGGAATAGGAGCTTTG

[0051] TTCCTTGGGTTCTTGGGAGCAGCAGGAAGCACTATGGGCGCAGCGTCA

[0052] ATGACGCTGACGGTACAGGCCAGACAATTATTGTCTGGTATAGTGCAG

[0053] CAGCAGAACAATTTGCTGAGGGCTATTGAGGCGCAACAGCATCTGTTG

[0054] CAACTCACAGTCTGGGGCATCAAGCAGCTCCAGGCAAGAATCCTGGCT

[0055] GTGGAAAGATACCTAAAGGATCAACAGCTCCTGGGGATTTGGGGTTGC

[0056] TCTGGAAAACTCATTTGCACCACTGCTGTGCCTTGGAATGCTAGTTGGA

[0057] GTAATAAATCTCTGGAACAGATTTGGAATCACACGACCTGGATGGAGT

[0058] GGGACAGAGAAAATTAACAATTACACAAGCTTAATACACTCCTTAATTG

[0059] AAGAATCGCAAAACCAGCAAGAAAGAATGAACAAGAATTATTGGAA

[0060] TTAGATAAATGGGCAAGTTTGTGGAATTGGTTTAACATAACAAATTGGC

[0061] TGTGGTATATAAAATTATTCATAATGATAGTAGGAGGCTTGGTAGGTTT

[0062] AAGAATAGTTTTTTGCTGTACTTTCTATAGTGAATAGAGTTAGGCAGGGA

[0063] TATTCACCATTATCGTTTCAGACCCACCTCCCAACCCCGAGGGACCCG

[0064] ACAGGCCCGAAGGAATAGAAGAAGAAGGTGGAGAGAGAGACAGAGAC

[0065] AGATCCATTCGATTAGTGAACGGATCTCGACGGTATCGTCGTCGGCGCC

[0066] GAATTCACAAATGGCAGTATTCATCCACAATTTTAAAAGAAAAGGGGG

[0067] GATTGGGGGGTACAGTGCAGGGAAAGAATAGTAGACATAATAGCAA

[0068] CAGACATACAAAACTAAAGAATTACAAAACAAATTACAAAAATTCAAA

[0069] ATTTTCGGGTTTATTACAGGGACAGCAGAAATCACTTTGGGGCGATAA

[0070] GCTTGGGAGTTCCGCGTTACATAACTTACGGTAAATGGCCCGCCTGGCT

[0071] GACCGCCCAACGACCCCCGCCCATTGACGTCAATAATGACGTATGTTCC

[0072] CATAGTAACGCCAATAGGGACTTTCCATTGACGTCAATGGGTGGAGTA

[0073] TTTACGGTAAACTGCCCACTTGGCAGTACATCAAGTGTATCATATGCCA

[0074] AGTACGCCCCCTATTGACGTCAATGACGGTAAATGGCCCGCCTGGCATT

[0075] ATGCCCAGTACATGACCTTAcGGGACTTTCCTACTTGGCAGTACATCTA

[0076] CGTATTAGTCATCGCTATTACCATGGTGATGCGGTTTTGGCAGTACAcC

[0077] AATGGGCGTGGATAGCGGTTTGACTCACGGGGATTTCCAAGTCTCCACC

[0078] CCATTGACGTCAATGGGAGTTTGTTTTGGCACCAAAATCAACGGGACTT

[0079] TCCAAAATGTCGTAACAACTCCGCCCCATTGACGCAAATGGGCGGTAG

[0080] GCGTGTACGGTGGGAGGTCTATATAAGCAGAGCTCGTTTAGTGAACCG

[0081] TCAGATCGCCTGGAGACGCCATCCACGCTGTTTTGACCTCCATAGAAGA

[0082] CACCGACtctagaAGCGCTTGTACAACTAGTGTTTAAACCCCGGGCTCGAG

[0083] GCTAGCggatccTAAgccagcccccgattgggggcgacactccaccatagatcactcccctgtgaggaacta

[0084] ctgtcttcacgcagaaagcgtctagccatggcgttagtatgagtgtcgtgcagcctccaggaccccccctcccgggag

[0085] agccatagtggtctgcggaaccggtgagtacaccggaattgccaggacgaccgggtcctttcttggatcaacccgctc

[0086] aatgcctggagatttgggcgtgcccccgcgagactgctagccgagtagtgttgggtcgcgaaaggccttgtggtactg

[0087] cctgatagggtgcttgcgagtgccccgggaggtctcgtagaccgtgcaccatgagcacgaatcctaaacctcaaaga

[0088] aaaaccaaacgtaacaccaacgggtttatggccaagcctttgtctcaagaagaatccaccctcattgaaagagcaacg

[0089] gctacaatcaacagcatccccatctctgaagactacagcgtcgccagcgcagctctctctagcgacggccgcatcttc

[0090] actggtgtcaatgtatatcattttactgggggaccttgtgcagaactcgtggtgctgggcactgctgctgctgcggcagc

[0091] tggcaacctgacttgtatcgtcgcgatcggaaatgagaacaggggcatcttgagcccctgcggacggtgccgacagg

[0092] tgcttctcgatctgcatcctgggatcaaagccatagtgaaggacagtgatggacagccgacggcagttgggattcgtg

[0093] aattgctgccctctggttatgtgtgggagggctaaGGTACCTTTAAGACCAATGACTTACAA

[0094] GGCAGCTGTAGATCTTAGCCACTTTTTAAAAGAAAAGGGGGGACTGGA

[0095] AGGGCTAATTCACTCCCAACGAAGACAAAATCGTCGAGAGATGCTGCA

[0096] TATAAGCAGCTGCTTTTTGCTTGTACTGGGTCTCTCTGGTTAGACCAGA

[0097] TCTGAGCCTGGGAGCTCTCTGGCTAACTAGGGAACCCACTGCTTAAGCC

[0098] TCAATAAAGCTTGCCTTGAGTGCTTCAAGTAGTGTGTGCCCGTCTGTTG

[0099] TGTGACTCTGGTAACTAGAGATCCCTCAGACCCTTTTAGTCAGTGTGGA

[0100] AAATCTCTAGCAGTAGTAGTTCATGTCATCTTATTATTCAGTATTTATAA

[0101] CTTGCAAAGAAATGAATATCAGAGAGTGAGAGGCCTTGACATTATAAT

[0102] AGATTTAGCAGGAATTGAACTAGGAGTGGAGCACACAGGCAAAGCTGC

[0103] AGAAGTACTTGGAAGAAGCCACCAGAGATACTCACGATTCTGCACATA

[0104] CCTGGCTAATCCCAGATCCTAAGGATTACATTAAGTTTACTAACATTTA

[0105] TATAATGATTTATAGTTAAGTATAAACTTATCTAATTTACTATTCTGA

[0106] CAGATATTAATTAATCCTCAAATATCATAAGATGATTACTATTATCC

[0107] CCATTTAACAAGGAAACTGAGAGGGAAAGATGTTGAAGTAATTT

[0108] TCCCACAATTACAGCATCCGTTAGTTACGACTCTATGATCTTCTGACAC

[0109] AAATTCCATTTACTCCTCACCCTATGACTCAGTCGAATATATCAAAGTT

[0110] ATGGACATTATGCTAAGTAACAAATTACCCTTTTATAGTAAATACTG

[0111] AGTAGATTGAGAGAAATTGTTTGCAAACCTGAATAGCTTCAAGAA

[0112] GAAGAGAAGTGAGGATAAGAATAACAGTTGTCATTTAACAAGTTTAA

[0113] CAAGTAACTTGGTTAGAAAGGGATTCAAATGCATAAAGCAAGGGATAA

[0114] ATTTTTCTGGCAACAAGACTATACAATATAACCTTAAATATGACTTCAA

[0115] ATAATTGTTGGAACTTGATAAAACTAATTAATTATTGAAGATTATC

[0116] AATATTATAATGTAATTTACTTTAAAAAGGGAACATAGAAATGTGTA

[0117] TCATTAGAGTAGAAAACAATCCTTATTCACAATTTGTCAAAACAAGT

[0118] TTGTTATTAACACAAGTAGAATACTGCATTCAATTAAGTTGACTGCAGA

[0119] TTTTGTGTTTTGTTAAAATTAGAAAGAGATAACAACAATTTGAATTATT

[0120] GAAAGTAACATGTGAGCAAAAGGCCAGCAAAAGGCCAGGAACCGTAA

[0121] AAAGGCCGCGTTGCTGGCGTTTTTCCATAGGCTCCGCCCCCCTGACGAG

[0122] CATCACAAAAATCGACGCTCAAGTCAGAGGTGGCGAAACCCGACAGGA

[0123] CTATAAAGATACCAGGCGTTTCCCCCTGGAAGCTCCCTCGTGCGCTCTC

[0124] CTGTTCCGACCCTGCCGCTTACCGGATACCTGTCCGCCTTTCTCCCTTCG

[0125] GGAAGCGTGGCGCTTTCTCATAGCTCACGCTGTAGGTATCTCAGTTCGG

[0126] TGTAGGTCGTTCGCTCCAAGCTGGGCTGTGTGCACGAACCCCCCGTTCA

[0127] GCCCGACCGCTGCGCCTTATCCGGTAACTATCGTCTTGAGTCCAACCCG

[0128] GTAAGACACGACTTATCGCCACTGGCAGCAGCCACTGGTAACAGGATT

[0129] AGCAGAGCGAGGTATGTAGGCGGTGCTACAGAGTTCTTGAAGTGGTGG

[0130] CCTAACTACGGCTACACTAGAAGAACAGTATTTGGTATCTGCGCTCTGC

[0131] TGAAGCCAGTTACCTTCGGAAAAAGAGTTGGTAGCTCTTGATCCGGCA

[0132] AACAAACCACCGCTGGTAGCGGTGGTTTTTTTGTTTGCAAGCAGCAGAT

[0133] TACGCGCAGAAAAAAAGGATCTCAAGAAGATCCTTTGATCTTTTCTACG

[0134] GGGTCTGACGCTCAGTGGAACGAAAACTCACGTTAAGGGATTTTGGTC

[0135] ATGAGATTATCAAAAAGGATCTTCACCTAGATCCTTTTAAATTAAAAAT

[0136] GAAGTTTTAAATCAATCTAAAGTATATATGAGTAAACTTGGTCTGACAG

[0137] ATGAGTATTCAACATTTCCGTGTCGCCCTTATTCCCTTTTTTGCGGCATT

[0138] TTGCCTTCCTGTTTTTGCTCACCCAGAAACGCTGGTGAAAGTAAAAGAT

[0139] GCTGAAGATCAGTTGGGTGCACGAGTGGGTTACATCGAACTGGATCTC

[0140] AACAGCGGTAAGATCCTTGAGAGTTTTCGCCCCGAAGAACGTTTTCCAA

[0141] TGATGAGCACTTTTAAAGTTCTGCTATGTGGCGCGGTATTATCCCGTAT

[0142] TGACGCCGGGCAAGAGCAACTCGGTCGCCGCATACACTATTCTCAGAA

[0143] TGACTTGGTTGAGTACTCACCAGTCACAGAAAAGCATCTTACGGATGG

[0144] CATGACAGTAAGAGAATTATGCAGTGCTGCCATAACCATGAGTGATAA

[0145] CACTGCGGCCAACTTACTTCTGACAACGATCGGAGGACCGAAGGAGCT

[0146] AACCGCTTTTTTGCACAACATGGGGGATCATGTAACTCGCCTTGATCGT

[0147] TGGGAACCGGAGCTGAATGAAGCCATACCAAACGACGAGCGTGACACC

[0148] ACGATGCCTGTAGCAATGGCAACAACGTTGCGCAAACTATTAACTGGC

[0149] GAACTACTTACTCTAGCTTCCCGGCAACAATTAATAGACTGGATGGAG

[0150] GCGGATAAAGTTGCAGGACCACTTCTGCGCTCGGCCCTTCCGGCTGGCT

[0151] GGTTTATTGCTGATAAATCTGGAGCCGGTGAGCGTGGGTCTCGCGGTAT

[0152] CATTGCAGCACTGGGGCCAGATGGTAAGCCCTCCCGTATCGTAGTTATC

[0153] TACACGACGGGGAGTCAGGCAACTATGGATGAACGAAATAGACAGATC

[0154] GCTGAGATAGGTGCCTCACTGATTAAGCATTGGTAACTGTCAGACCAA

[0155] GTTTACTCATATATACTTTAGATTGATTTAAAACTTCATTTTTAATTTAA

[0156] AAGGATCTAGGTGAAGATCCTTTTTGATAATCTCATGACCAAAATCCCT

[0157] TAACGTGAGTTTTCGTTCCACTGAGCGTCAGACCCCGTAGAAAAGATCA

[0158] AAGGATCTTCTTGAGATCCTTTTTTTCTGCGCGTAATCTGCTGCTTGCAA

[0159] ACAAAAAAACCACCGCTACCAGCGGTGGTTTGTTTGCCGGATCAAGAG

[0160] CTACCAACTCTTTTTCCGAAGGTAACTGGCTTCAGCAGAGCGCAGATAC

[0161] CAAATACTGTCCTTCTAGTGTAGCCGTAGTTAGGCCACCACTTCAAGAA

[0162] CTCTGTAGCACCGCCTACATACCTCGCTCTGCTAATCCTGTTACCAGTG

[0163] GCTGCTGCCAGTGGCGATAAGTCGTGTCTTACCGGGTTGGACTCAAGAC

[0164] GATAGTTACCGGATAAGGCGCAGCGGTCGGGCTGAACGGGGGGTTCGT

[0165] GCACACAGCCCAGCTTGGAGCGAACGACCTACACCGAACTGAGATACC

[0166] TACAGCGTGAGCATTGAGAAAGCGCCACGCTTCCCGAAGGGAGAAAGG

[0167] CGGACAGGTATCCGGTAAGCGGCAGGGTCGGAACAGGAGAGCGCACG

[0168] AGGGAGCTTCCAGGGGGAAACGCCTGGTATCTTTATAGTCCTGTCGGGT

[0169] TTCGCCACCTCTGACTTGAGCGTCGATTTTTGTGATGCTCGTCAGGGGG

[0170] GCGGAGCCTATGGAAAAACGCCAGCAACGCGGCCTTTTTACGGTTCCT

[0171] GGCCTTTTGCTGGCCTTTTGCTCACATGTTCTTTCCTGCGTTATCCCCTG

[0172] ATTCTGTGGATAACCGTATTACCGCCTTTGAGTGAGCTGATACCGCTCG

[0173] CCGCAGCCGAACGACCGAGCGCAGCGAGTCAGTGAGCGAGGAAGCGG

[0174] AAGAGCGCCCAATACGCAAACCGCCTCTCCCCGCGCGTTGGCCGATTC

[0175] ATTAATGCAGCTGTGGAATGTGTGTCAGTTAGGGTGTGGAAAGTCCCC

[0176] AGGCTCCCCAGCAGGCAGAAGTATGCAAAGCATGCATCTCAATTAGTC

[0177] AGCAACCAGGTGTGGAAAGTCCCCAGGCTCCCCAGCAGGCAGAAGTAT

[0178] GCAAAGCATGCATCTCAATTAGTCAGCAACCATAGTCCCGCCCCTAACT

[0179] CCGCCCATCCCGCCCCTAACTCCGCCCAGTTCCGCCCATTCTCCGCCCC

[0180] ATGGCTGACTAATTTTTTTTATTTATGCAGAGGCCGAGGCCGCCTCGGC

[0181] CTCTGAGCTATTCCAGAAGTAGTGAGGAGGCTTTTTTGGAGGCCTAGGC

[0182] TTTTGCAAAAAGCTTGGACACAAGACAGGCTTGCGAGATATGTTTGAG

[0183] AATACCACTTTATCCCGCGTCAGGGAGAGGCAGTGCGTAAAAAGACGC

[0184] GGACTCATGTGAAATACTGGTTTTTAGTGCGCCAGATCTCTATAATCTC

[0185] GCGCAACCTATTTTCCCCTCGAACACTTTTTAAGCCGTAGATAAACAGG

[0186] CTGGGACACTTCACATGAGCGAAAAATACATCGTCACCTGGGACATGT

[0187] TGCAGATCCATGCACGTAAACTCGCAAGCCGACTGATGCCTTCTGAAC

[0188] AATGGAAAGGCATTATTGCCGTAAGCCGTGGCGGTCTGTACCGGGTGC

[0189] GTTACTGGCGCGTGAACTGGGTATTCGTCATGTCGATACCGTTTGTATT

[0190] TCCAGCTACGATCACGACAACCAGCGCGAGCTTAAAGTGCTGAAACGC

[0191] GCAGAAGGCGATGGCGAAGGCTTCATCGTTATTGATGACCTGGTGGAT

[0192] ACCGGTGGTACTGCGGTTGCGATTCGTGAAATGTATCCAAAAGCGCAC

[0193] TTTGTCACCATCTTCGCAAAACCGGCTGGTCGTCCGCTGGTTGATGACT

[0194] ATGTTGTTGATATCCCGCAAGATACCTGGATTGAACAGCCGTGGGATAT

[0195] GGGCGTCGTATTCGTCCCGCCAATCTCCGGTCGCTAATCTTTTCAACGC

[0196] CTGGCACTGCCGGGCGTTGTTCTTTTTAACTTCAGGCGGGTTACAATAG

[0197] TTTCCAGTAAGTATTCTGGAGGCTGCATCCATGACACAGGCAAACCTGA

[0198] GCGAAACCCTGTTCAAACCCCGCTTTAAACATCCTGAAACCTCGACGCT

[0199] AGTCCGCCGCTTTAATCACGGCGCACAACCGCCTGTGCAGTCGGCCCTT

[0200] GATGGTAAAACCATCCCTCACTGGTATCGCATGATTAACCGTCTGATGT

[0201] GGATCTGGCGCGGCATTGACCCACGCGAAATCCTCGACGTCCAGGCAC

[0202] GTATTGTGATGAGCGATGCCGAACGTACCGACGATGATTTATACGATA

[0203] CGGTGATTGGCTACCGTGGCGGCAACTGGATTTATGAGTGGGCCCCGG

[0204] ATCTTTGTGAAGGAACCTTACTTCTGTGGTGTGACATAATTGGACAAAC

[0205] TACCTACAGAGATTTAAAGCTCTAAGGTAAATATAAAATTTTTAAGTGT

[0206] ATAATGTGTTAAACTACTGATTCTAATTGTTTGTGTATTTTAGATTCCAA

[0207] CCTATGGAACTGATGAATGGGAGCAGTGGTGGAATGCCTTTAATGAGG

[0208] AAAACCTGTTTTGCTCAGAAGAAATGCCATCTAGTGATGATGAGGCTA

[0209] CTGCTGACTCTCAACATTCTACTCCTCCAAAAAAGAAGAGAAAGGTAG

[0210] AAGACCCCAAGGACTTTCCTTCAGAATTGCTAAGTTTTTTGAGTCATGC

[0211] TGTGTTTAGTAATAGAACTCTTGCTTGCTTTGCTATTTACACCACAAAG

[0212] GAAAAAGCTGCACTGCTATACAAGAAAATTATGGAAAAATATTCTGTA

[0213] ACCTTTATAAGTAGGCATAACAGTTATAATCATAACATACTGTTTTTTC

[0214] TTACTCCACACAGGCATAGAGTGTCTGCTATTAATAACTATGCTCAAAA

[0215] ATTGTGTACCTTTAGCTTTTTAATTTGTAAAGGGGTTAATAAGAAT

[0216] TTGATGTATAGTGCCTTGACTAGAGATCATAATCAGCCATACCACATTT

[0217] GTAGAGGTTTTACTTGCTTTAAAACCTCCCACACCTCCCCCTGAACC

[0218] TGAAACATAAAATGAATGCAATTGTTGTTGTTAACTTGTTTATTGCAGC

[0219] TTATAATGGTTACAAATAAAGCAATAGCATCACAAATTTCACAAATAA

[0220] AGCATTTTTTTCACTGCATTCTAGTTGTGGTTTGTCCAAACTCATCAATG

[0221] TATCTTATCATGTCTGGATCAACTGGATAACTCAAGCTAACCAAAATCA

[0222] TCCCAAACTTCCCACCCCATACCCTATTACCACTGCCAATTACCTAGTG

[0223] GTTTCATTTACTCTAAACCTGTGATTCCTCTGAATTATTTTCATTTTAAAGAAATTGTATTTGTTAAATATGTACTACAAACTTAGTAGT (as shown in SEQ ID NO: 7).

[0224] The present invention also provides a method for preparing the above-mentioned lentiviral recombinant vector, wherein the enzyme-digested lentiviral vector is ligated with the nucleic acid molecule and the fluorescent protein gene to obtain the lentiviral recombinant vector.

[0225] The present invention also provides lentiviruses, transformation and / or transfection of the above-described lentivirus recombinant vectors and / or lentivirus recombinant vectors obtained by the above preparation methods.

[0226] In some embodiments of the present invention, the cells transformed and / or transfected in the lentivirus described above include HEK-293 cells.

[0227] The present invention also provides cell lines for transformation and / or transfection with the above-mentioned lentiviruses.

[0228] In some embodiments of the present invention, the cells in the above-described cell lines, the transformed and / or transfected cells, include: A549 cells and / or HeLa cells.

[0229] The present invention also provides the use of the above-mentioned protease recognition enzyme, the above-mentioned nucleic acid molecule, the above-mentioned lentiviral recombinant vector, the lentiviral recombinant vector obtained by the above-mentioned preparation method, the above-mentioned lentivirus and / or the above-mentioned cell line in any of the following:

[0230] (I) Preparation of a kit for detecting proteasome activity; and / or

[0231] (II) Screening for proteasome activity inhibitors and / or proteasome activity activators;

[0232] In some embodiments of the present invention, the detection in the above application includes the following steps: mixing the sample to be tested with the cell line; when fluorescence appears, the sample to be tested inhibits proteasome activity; when no fluorescence appears, the sample to be tested does not inhibit proteasome activity.

[0233] This invention provides a protease recognition enzyme having:

[0234] (1) An amino acid sequence as shown in SEQ ID NO:1; or

[0235] (2) An amino acid sequence obtained by substituting, deleting, or adding one or more amino groups to the amino acid sequence shown in (1), and which has the same or similar function as the amino acid sequence shown in (1); or

[0236] (3) An amino acid sequence that is at least 80% identical to the amino acid sequence shown in (1) or (2).

[0237] This invention constructs A549-EGFPc and HeLa-EGFPc cell lines for detecting intracellular proteasome activity. Compared to existing protease recognition enzymes, the cell lines designed in this invention significantly improve the detection efficiency of proteasome activity. When proteasome activity decreases, the protease recognition enzyme in this invention exhibits a 30-40% higher sensitivity and recognition efficiency compared to existing sequences. As proteasome activity decreases, the efficiency of recognizing and degrading EGFP protein also decreases, allowing for the normal expression and accumulation of green fluorescent EGFP. The degree of proteasome activity reduction can be quantitatively determined by observing the expression of green fluorescence in the A549-EGFPc and HeLa-EGFPc cell lines. The detection system of this invention also demonstrates significant detection efficiency for proteasome damage directly caused by viral infections, compensating for the inability to quantitatively detect viral-induced proteasome damage. Furthermore, the A549-EGFPc and HeLa-EGFPc cell lines constructed in this invention remain stable after 50 passages. Therefore, the detection system constructed in this invention can quantitatively detect proteasome activity with high sensitivity, high stability, and a wide range, possessing broad application prospects and industrial value. Attached Figure Description

[0238] To more clearly illustrate the technical solutions in the embodiments of the present invention or the prior art, the accompanying drawings used in the description of the embodiments or the prior art will be briefly introduced below.

[0239] Figure 1 After adding the proteasome activity inhibitor MG132 to the successfully constructed A549-EGFPc cell line to cause proteasome damage, Western blot was used to detect the EGFP expression in the A549-EGFPc cell line; the left band (Mock) represents the control group with 10 μM DMSO, and the right band represents the group with 10 μM MG132.

[0240] Figure 2The images show the proteasome activity detection of the successfully constructed A549-EGFPc cell line. When the proteasome is damaged by MG132, the A549-EGFPc cell line exhibits significant green fluorescence. The top image shows fluorescence images with DMSO added, from left to right: images under a normal microscope, images of cells after DAPI staining of the nucleus, images of cells showing green fluorescence, and images of all fluorescence samples merged. The bottom image shows fluorescence images with MG132 added, from left to right: images of cells under a normal microscope, images of cells after DAPI staining of the nucleus, images of cells showing green fluorescence, and images of all fluorescence samples merged.

[0241] Figure 3 The modified EGFP protease fusion recognition sequence (SGLRSRAQASNSAVDGTACENWFSSLSHFVIHL) used in this invention exhibits better fusion performance and a more significant function in detecting proteasome activity compared to the sequence in Comparative Example 1 (ACKNWFSSLSHFVIHL). The upper image shows the fluorescence of Comparative Example 1, where the previous proteasome recognition sequence (ACKNWFSSLSHFVIHL) was used. From left to right, the sequence shows staining of the cell nucleus (DAPI), cell proteasome damage after the addition of a proteasome inhibitor (green), and co-localization (merge) of the cell nucleus and green fluorescence. The lower image shows the fluorescence of the modified proteasome recognition sequence used in this invention. From left to right, the sequence shows staining of the cell nucleus (DAPI), cell proteasome damage after the addition of a proteasome inhibitor (green), and co-localization (merge) of the cell nucleus and green fluorescence.

[0242] Figure 4 As shown in the comparison with Comparative Example 1, the A549-EGFPc cell line constructed in this invention significantly improves the detection efficiency of proteasome activity.

[0243] Figure 5 After adding the proteasome activity inhibitor MG132 to the successfully constructed Hela-EGFPc cell line to induce proteasome damage, Western blot was used to detect EGFP expression in the A549-EGFPc cell line. The left band (Mock) represents the control group treated with 10 μM DMSO, and the right band represents the group treated with 10 μM MG132.

[0244] Figure 6The images show the proteasome activity detection of the successfully constructed Hela-EGFPc cell line. When the proteasome is damaged by MG132, the Hela-EGFPc cell line exhibits significant green fluorescence. The top image shows fluorescence images with DMSO added, from left to right: normal microscope image, DAPI-stained cell image, green fluorescence detection image, and a merged group of all fluorescence results. The bottom image shows fluorescence images with MG132 added, from left to right: normal microscope image, DAPI-stained cell image, green fluorescence detection image, and a merged group of all fluorescence results.

[0245] Figure 7 The application of the constructed Hela-EGFPc cell line proteasome detection system is shown: H1N1 infection can significantly inhibit proteasome activity; The top image shows fluorescence images after adding DMSO, from left to right: a microscopic image of the cell nucleus after DAPI staining (blue), an image of H1N1 protein NP after antibody staining (red), an image of cell proteasome activity detection (green), and a merged group of all fluorescence; the bottom image shows fluorescence images after adding H1N1 virus, from left to right: a microscopic image of the cell nucleus after DAPI staining (blue), an image of H1N1 protein NP after antibody staining (red), an image of cell proteasome activity detection (green), and a merged group of all fluorescence.

[0246] Figure 8 The application of the constructed Hela-EGFPc cell line proteasome detection system is shown: CVB3 virus infection significantly improves proteasome activity, which is beneficial to the translation and assembly of viral proteins. Western blot was used to detect proteasome activity in the Hela-EGFPc cell line. From left to right: no CVB3 virus and no proteasome inhibitor MG132, no CVB3 virus but with proteasome inhibitor MG132, CVB3 virus and proteasome inhibitor MG132, and no CVB3 virus but with proteasome inhibitor MG132. The structural protein VP1 of CVB3 was visualized. HA, EGFP and β-Actin are three proteins;

[0247] Figure 9After 50 passages, both A549-EGFPc and HeLa-EGFPc cell lines maintained stable proteasome detection efficiency. The top image shows fluorescence images of proteasome activity in A549-EGFPc cells after 50 passages, from left to right: microscopic images of cells with DAPI-stained nuclei, microscopic images of cells detecting green fluorescence, and a merged group of all fluorescence levels. The bottom image shows fluorescence images of proteasome activity in HeLa-EGFPc cells after 50 passages, from left to right: microscopic images of cells with DAPI-stained nuclei, microscopic images of cells detecting green fluorescence, and a merged group of all fluorescence levels.

[0248] Figure 10 A schematic diagram of the proteasome activity detection system is shown. Detailed Implementation

[0249] This invention discloses an A549-EGFPc and Hela-EGFPc cell line that can be used to detect intracellular proteasome activity. When proteasome activity decreases, obvious green fluorescence can be observed in the A549-EGFPc and Hela-EGFPc cell lines using a fluorescence microscope. Therefore, the A549-EGFPc and Hela-EGFPc cell lines constructed in this invention can be used to detect intracellular proteasome activity.

[0250] It should be understood that the expression “one or more of…” individually includes each of the objects described after the expression, as well as various different combinations of two or more of the described objects, unless otherwise understood from the context and usage. The expression “and / or” combined with three or more described objects should be understood to have the same meaning, unless otherwise understood from the context.

[0251] The terms “including,” “having,” or “containing,” including the use of their grammatical synonyms, should generally be understood as open-ended and non-restrictive, for example, not excluding other unstated elements or steps, unless otherwise specifically stated or understood from the context.

[0252] It should be understood that the order of the steps or the order in which certain actions are performed is not important as long as the invention remains operational. Furthermore, two or more steps or actions can be performed simultaneously.

[0253] The use of any and all instances or exemplary language such as “e.g.” or “including” in this document is merely intended to better illustrate the invention and is not intended to limit the scope of the invention unless the claims are made. No language in this specification should be construed as indicating that any unclaimed element is essential to the practice of the invention.

[0254] Furthermore, the numerical ranges and parameters used to define the present invention are approximate values, and the relevant values ​​in the specific embodiments have been presented as precisely as possible. However, any value inevitably contains standard deviations due to individual test methods. Therefore, unless explicitly stated otherwise, it should be understood that all ranges, quantities, values, and percentages used in this disclosure are modified with the word "approximately." Here, "approximately" generally means an actual value within plus or minus 10%, 5%, 1%, or 0.5% of a particular value or range.

[0255] The principle of the proteasome activity detection system is as follows: Figure 9 As shown, the proteasome recognition signal CL-1 is added to the end of EGFP to form the recombinant protein EGFPc. ① When the proteasome system activity is normal, the EGFPc protein is rapidly degraded, and EGFP green fluorescence cannot be expressed normally in the cell. ② When the proteasome system activity is inhibited, the proteasome system's ability to degrade EGFPc protein is significantly weakened, and EGFPc cannot be degraded in time, thus green fluorescence is expressed normally. The increased intensity of intracellular EGFP green fluorescence can be directly observed using a fluorescence microscope. Cellular fluorescence images are captured and analyzed using image processing software such as ImageJ, thereby achieving real-time, dynamic, and quantitative detection of changes in intracellular proteasome system activity without affecting normal cellular life processes.

[0256] In Example 1, Comparative Example 1, and Verification Examples 1 to 4 of this invention, BSD is: Blastidin S (blast fungicide, BSR / BSD screening antibiotic).

[0257] In Example 1, Comparative Example 1, and Verification Examples 1 to 4 of this invention, the raw materials and reagents used can all be purchased from the market.

[0258] The present invention will be further illustrated below with reference to the embodiments:

[0259] Example 1: Construction steps of A549-EGFPc and HeLa-EGFPc cell lines

[0260] 1. Digest pTrip-BSD-EGFPc plasmid with enzymes.

[0261] ① Restriction digestion of the blank vector pTrip-BSD. 1.5 μg of plasmid was digested with NEB enzymes XbaI and BamHI for 2 hours. The digestion system was as follows:

[0262]

[0263] Enzyme digestion for 2 hours, gel recovery

[0264] ②PCR amplification of the target gene EGFPc

[0265] Primer selection

[0266] F1:tctagaATGGTGAGCAAGGGCGAGGAGCTGTT (as shown in SEQ ID NO:4)

[0267] F2:TTAggatccGAGGTGGATCACAAAGTGAGAGAGGCTGCTAAACC AGTTCTCGCAGGCGGTACCGTCGACTGCAGAATTCGAAGCTTGAGCTC GAGATCTGAGTCCGGACTTGTACAGCTCGTCCATGCCGAGAGTGATCCC G (as shown in SEQ ID NO: 5)

[0268] Perform PCR amplification using the following procedure:

[0269]

[0270]

[0271] Among them, (2), (3), and (4) are loop steps, and the loop count is 40 times;

[0272] After PCR, the gel was recovered and digested using New England Biolabs (NEB) enzymes XbaI and BamHI.

[0273] ③ Ligation: The pTrip-BSD plasmid digested with XbaI and BamHI was ligated with the target gene EGFPc (EGFP+CL-1) digested with XbaI and BamHI. The ligation was carried out at 16℃ for two hours.

[0274] The reaction system is as follows: The reaction conditions are 16℃ for two hours.

[0275]

[0276] ④ Transformation: Add all the ligation products obtained in step ② to 100 μL of DH5α, and finally take 120 μL and plate it with ampicillin (crystallize at 37 degrees Celsius).

[0277] 2. Generate lentiviruses:

[0278] ① Cell plating: HEK-293 cells were plated at a density of 4.5*10-1 5 / mL in a 6-well plate;

[0279] ② Plasmid transfection of HEK-293 cells:

[0280] The plasmid was transfected into HEK-293 cells using a DNA transfection kit (Entranster™-H4000; Engreen Biosystem Co, Ltd.; Cat. No. 4000-05). The transfection system was as follows:

[0281]

[0282] ③ The order of adding samples to the transfection system is as follows: First, add 200 μL of opti-MEM to a 1.5 EP tube, then add VSV-G (add below the liquid level), then add gap (add below the liquid level), and finally add pTrip-BSD-EGFPc (add below the liquid level). Mix well (or blow well with the pipette tip), add LT1 transfection reagent, mix well (or blow well with the pipette tip), and let stand for 15 minutes.

[0283] ④ When HEK293 cells grow to 80%-90%, remove the original culture medium and replace each 6-well well with 1.2 mL of 3% FBS culture medium. After the plasmids are incubated, insert them into the wells in a circular motion.

[0284] ⑤ After 6-8 hours, replace each well with 1.6 mL of 3% FBS culture medium and continue culturing until virus harvesting. Harvest the virus after 2 days of incubation at 37°C.

[0285] ⑥ Collect lentivirus after 2 days of incubation: Collect the supernatant, filter it through a 0.45 filter membrane into a 1.5 mL EP tube, calculate the volume of the supernatant, then dilute each EP tube 40 times by volume and add Hepes; then add polybrene to each EP tube by volume (mL) * 0.8 (final unit is μL) and mix well by pipetting.

[0286] ⑦ Aliquoting and labeling: Aliquot into 320μL tubes and store at -80 degrees Celsius.

[0287] 3. Establish A549-EGFPc and Hela-EGFPc cell lines

[0288] Establish stable A549-EGFPc and Hela-EGFPc cell lines:

[0289] ① The newly revived A549 and HeLa cell lines were subjected to a 1.5*10⁻⁶ ppm in vitro. 5 Cells / mL were seeded into 6-well plates.

[0290] ② Transduction the next day: First, a transduction buffer needs to be prepared. Calculate 700 μL of 10% full culture for a 6-well container, and add polybrane (in μL) at 0.8 times the volume. Then, add 300 μL of the coated lentivirus obtained in step 2 (prepared by aliquoting 320 μL) to the 700 μL transduction buffer below the surface of the liquid. Mix well, being careful to avoid air bubbles.

[0291] ③ Remove the culture medium from the original cell line, add 1 mL of virus mixture, label the passage number, place it in an incubator, and after 6-8 hours, remove the supernatant, add 2 mL of 10% FBS whole culture, and incubate for 2 days.

[0292] ④ Screening after two days: When the cells are confluent, wash once with 1 mL of PBS, add 200 μL of trypsin for digestion, stop digestion with 1 mL of DMEM containing 10% FBS (containing BSD, working concentration is 5 μg / mL), and then pipette the cells to ensure that all cells are blown off and appear as single cells. You can observe them under a microscope. Pay attention to this process as well.

[0293] ⑤ Add the cells blown off to a T25 flask and add 5 mL of complete culture (at this point, it is DMEM containing 10% FBS with 5 μg / mL BSD).

[0294] ⑥ Change the medium every 2-3 days. When all cells in the control group have died, passage the cells and perform BSD screening for 2-3 generations.

[0295] ⑦ Once the cells are stable, the constructed cell line is cryopreserved.

[0296] Validation of the A549-EGFPc cell line constructed in Example 1

[0297] ① Western blot verification:

[0298] The proteasome inhibitor MG132 can inhibit proteasome activity. After adding 10 μM MG132 to the A549-EGFPc cell line and incubating with MG132 for 12 h, the A549-EGFPc cells were lysed. Western blot showed obvious EGFP bands, proving that the proteasome was significantly inhibited.

[0299] ② Green fluorescence verification:

[0300] The proteasome inhibitor MG132 can inhibit proteasome activity. After adding 10 μM MG132 to the A549-EGFPc cell line and incubating with MG132 for 12 h, obvious green fluorescence was observed under a fluorescence microscope, proving that the proteasome was significantly inhibited and the degradation of the EGFP gene was significantly reduced, showing green fluorescence.

[0301] Comparative Example 1

[0302] The modified sequence used in this invention has significantly improved fluorescence efficiency compared to previously used sequences.

[0303] like Figure 3 and Figure 4 As shown, existing technologies use the ACKNWFSSLSHFVIHK sequence (as shown in SEQ ID NO:3) (Bence, Neil F et al. Methods in enzymology), as Comparative Example 1. This comparative example, using this sequence, showed that the A549-EGFPc constructed with it had very low proteasome activity. The A549-EGFPc constructed using the sequence SGLRSRAQASNSAVDGTACENWFSSLSHFVIHL (as shown in SEQ ID NO:1) of this invention showed significantly improved proteasome activity. Verification Example 2 validated the HeLa-EGFPc cell line constructed with this sequence.

[0304] ① Western blot verification:

[0305] like Figure 5 As shown, the proteasome inhibitor MG132 can inhibit proteasome activity. After adding 10 μM MG132 to the Hela-EGFPc cell line and incubating with MG132 for 12 h, Hela-EGFPc cells were lysed, and Western blot showed obvious EGFP bands, proving that the proteasome was significantly inhibited.

[0306] ② Green fluorescence verification:

[0307] like Figure 6 As shown, the proteasome inhibitor MG132 can inhibit proteasome activity. After adding 10 μM MG132 to the Hela-EGFPc cell line and incubating with MG132 for 12 h, obvious green fluorescence was observed under a fluorescence microscope, proving that the proteasome was significantly inhibited and the degradation of the EGFP gene was significantly weakened, showing green fluorescence.

[0308] The application of the A549-EGFPc cell line constructed in Example 3 was validated.

[0309] like Figure 7 As shown, after infection with H1N1 avian influenza virus, A549-EGFPc cells exhibited significant green fluorescence under a fluorescence microscope, demonstrating that H1N1 avian influenza infection significantly inhibited proteasome activity, resulting in a significant reduction in proteasome degradation of the EGFP gene. This demonstrates the application of the Hela-EGFPc cell line constructed in Example 4 to verify the green fluorescence.

[0310] Infection of the Hela-EGFPc cell line with Coxsackievirus B3 (CVB3) followed by lysis of Hela-EGFPc cells revealed a clear EGFP band in Western blot analysis, demonstrating significant proteasome inhibition. This indicates that CVB3 virus infection significantly inhibits proteasome activity, resulting in a significant reduction in proteasome degradation of the EGFP gene.

[0311] The above description is only a preferred embodiment of the present invention. It should be noted that for those skilled in the art, several improvements and modifications can be made without departing from the principle of the present invention, and these improvements and modifications should also be considered within the scope of protection of the present invention.

Claims

1. A polypeptide, characterized in that, The amino acid sequence of the polypeptide is shown in SEQ ID NO:

1.

2. A nucleic acid molecule encoding the polypeptide as described in claim 1, characterized in that, The nucleic acid sequence of the nucleic acid molecule is shown in SEQ ID NO:

2.

3. A lentiviral recombinant vector, characterized in that, Includes the nucleic acid molecules, fluorescent protein genes, and lentiviral vectors as described in claim 2.

4. The lentiviral recombinant vector as described in claim 3, characterized in that, The fluorescent protein gene is the EGFP gene.

5. The method for preparing the lentiviral recombinant vector as described in claim 3 or 4, characterized in that, The enzyme-digested lentiviral vector is ligated with the nucleic acid molecule and the fluorescent protein gene to obtain the lentiviral recombinant vector.

6. A cell line, characterized in that, The cell line contains the lentiviral recombinant vector as described in claim 3 or 4.

7. The cell line as described in claim 6, characterized in that, The cell type is either A549 cells or HeLa cells.

8. The use of the polypeptide of claim 1, the nucleic acid molecule of claim 2, the lentiviral recombinant vector of claim 3 or 4, the lentiviral recombinant vector obtained by the preparation method of claim 5, or the cell line of claim 6 or 7 in any of the following: (I) Preparation of a kit for detecting proteasome activity; and / or (II) Screening for proteasome activity inhibitors.

Citation Information

Patent Citations

  • Lentiviral vector of fusion green fluorescent protein with over expression of RAB7A and EGFP genes, building method and application thereof

    CN104531762A

  • Cell line used for detecting hepatitis A virus titer as well as construction method and application thereof

    CN107881152A